公开(公告)号：EP4357364A1

公开(公告)日：2024-04-24

申请号：EP22914112.2

申请日：2022-12-07

申请人： Hefei TG Immunopharma Co., Ltd.

发明人： TIAN, Zhigang ,  CAO, Guoshuai ,  XIAO, Weihua ,  SUN, Rui ,  SUN, Haoyu

IPC分类号： C07K16/28 ,  G01N33/574 ,  C12N15/13 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P31/00

摘要： Disclosed is an antibody and use thereof. The antibody or antigen binding fragment includes CDR sequences selected from at least one of heavy-chain variable region CDR sequences: SEQ ID NOs: 1-3; and light-chain variable region CDR sequences: SEQ ID NOs: 4-6. The antibody prepared by the present disclosure can effectively bind to the α3 domain of MICA or MICB, and further, promote the binding of NKG2D to MICA and/or MICB, and can effectively treat or prevent related diseases mediated by MICA and/or MICB, such as promoting the killing of tumors by NK cell.

公开(公告)号：EP4190815A1

公开(公告)日：2023-06-07

申请号：EP22766246.7

申请日：2022-03-07

申请人： Hefei TG Immunopharma Co., Ltd.

发明人： TIAN, Zhigang ,  LI, Yangyang ,  XIAO, Weihua ,  SUN, Rui ,  SUN, Haoyu

IPC分类号： C07K16/28 ,  C12N15/13 ,  A61P35/00 ,  A61K39/395 ,  G01N33/574

摘要： Provided is an antibody or antibody fragment. The antibody or the antibody fragment includes HCDR1 selected from GYTFSSFS, GYTFSTFA, or GYSFTAYT, HCDR2 selected from ILPGSNST, ILPGINNT, ILPGGNNT, or INPYNGGT, and HCDR3 selected from SSYWFAY, STYWFAY, or AREGNYYGSRGDFDY; and LCDR1 selected from QSLLNSGNQKNY or QTIVTN, LCDR2 selected from GAS or YAS, and LCDR3 selected from QNAHSYPPT, QNAHSYPPA, or QQSHSWPFT. The provided antibody can be used for treating cancer.

公开(公告)号：EP4321536A1

公开(公告)日：2024-02-14

申请号：EP22902772.7

申请日：2022-06-22

申请人： Hefei TG Immunopharma Co., Ltd.

发明人： TIAN, Zhigang ,  CHENG, Ying ,  XIAO, Weihua ,  CAO, Guoshuai ,  SUN, Haoyu ,  SUN, Rui

IPC分类号： C07K16/46 ,  C12N15/13 ,  G01N33/68 ,  G01N33/574

摘要： Provided are a bispecific antibody and use thereof. The recombinant antibody includes: a CDR sequence selected from at least one of CD3 antibody variable region CDR sequences: SEQ ID NO: 1 to SEQ ID NO: 6, and B7H6 antibody variable region CDR sequences: SEQ ID NO: 7 to SEQ ID NO: 12; or an amino acid sequence having at least 95% identity thereto. The recombinant antibodies prepared according to the present application can simultaneously target CD3 and B7H6 antigens, and they have a significantly prolonged half-life, exhibiting a stronger tumor-inhibiting ability than single-target antibodies.

公开(公告)号：EP4378956A1

公开(公告)日：2024-06-05

申请号：EP22903484.8

申请日：2022-12-07

申请人： Hefei TG Immunopharma Co., Ltd.

发明人： TIAN, Zhigang ,  CAO, Guoshuai ,  XIAO, Weihua ,  SUN, Rui ,  SUN, Haoyu

IPC分类号： C07K16/28 ,  C12N15/13 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  A61P37/06 ,  A61P31/00 ,  C12N5/07 ,  C12N15/11 ,  C12N15/63 ,  G01N33/68 ,  G01N33/577 ,  G01N33/574

摘要： The present disclosure discloses a B7H6 antibody and use thereof. The antibody includes heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3; and light chain CDR1, light chain CDR2 and light chain CDR3. The antibody of the present disclosure is capable of binding to B7H6, and promoting the binding of B7H6 to the NK cell activating receptor NKp30, with an anti-cancer function.